CCR2 and metabolic dysfunction-associated steatohepatitis: Recently, pharmacological inhibition of MCP-1 or the lack of CCR2 expression (MCP-1 receptor) in a murine model of NASH was shown to decrease liver inflammation and steatosis without affecting hepatic fibrogenesis [52], [53].